



Advicenne welcomes within its team, Advicenne welcomes within its team, Catherine Martre, as Head of Strategy and Commercial Development

Nîmes, February 1st, 2014 – Advicenne, a late-stage biopharmaceutical company focused on the development of paediatric friendly therapeutics for the treatment of orphan renal and neurological diseases announces the nomination of Catherine Martre, as Head of Strategy and Commercial Development.

Graduated from the Ecole Centrale and holder of a DEA (Diplôme des Etudes Approfondies equivalent to Master of Advanced Studies) in applied chemistry and process engineering, Catherine Martre started her career as a consultant within Alcimed, dedicated to strategy consulting for health and biotechnology companies. She then joined the pharmaceutical industry in 2001. She worked for Laboratoires Altana and then Nycomed where she was responsible for market research, data management, business development and commercial effectiveness. Prior to joining Advicenne she held the position of Director of Strategy and Public Affairs at Laboratoire Takeda France, in charge of strategy, business development and public affairs, including the negotiation with French Health authorities for pricing and reimbursement of new drugs.

Within Advicenne, Catherine Martre will be responsible for business development, economic affairs (pricing and reimbursement) and the marketing strategy for products of Advicenne's portfolio, whether developed internally or as a result of partnerships. Doctor Luc-André Granier, founder and CEO of Advicenne, is delighted that Ms Martre has joined the Advicenne team, "this recruitment is of essential strategic importance at a time when Advicenne Pharma is beginning to market its first products in Europe".

###

For further information, please contact:

Advicenne

LA Granier, S Delbaere, J Rachline

info@advicenne.com

+33 (0)4 66 05 54 20

About Advicenne

Advicenne is a late-stage biopharmaceutical company focusing on the development of paediatric friendly therapeutics for the treatment of orphan renal and neurological diseases. The Company has a strong portfolio of products in late-stage development targeting critical unmet needs in nephrology and neurology. Advicenne also develops a clinical and pre-clinical pipeline of potential treatments for additional orphan diseases in collaboration with Key Opinion Leaders.

The Company was established in 2007 in Nimes (France). Since its inception, the Company has raised close to €30 million in equity from leading venture capital investors Innobio (Bpifrance), IXO Private Equity, IRDI SORIDEC Gestion, Cemag Invest and MI Care.